Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,052,302 papers from all fields of science
Search
Sign In
Create Free Account
FIGO Stage IIB
A FIGO stage term that applies to gynecologic cancers. For cervical cancer, it refers to cancer that invades beyond the cervix, but not to the pelvic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Stage IIB Ovarian Cancer
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Size of cervical lesion in locally advanced carcinoma cervix and response to neoadjuvant chemotherapy
N. Ahirwar
International Journal of Reproduction…
2019
Corpus ID: 207822592
Background: Recently neoadjuvant chemotherapy has started being considered for advanced stage of carcinoma cervix. Drug delivery…
Expand
2016
2016
Implementation of image-guided brachytherapy (IGBT) for patients with uterine cervix cancer: a tumor volume kinetics approach
H. Carvalho
,
L. Mendez
,
+7 authors
R. Baroni
Journal of Contemporary Brachytherapy
2016
Corpus ID: 17058233
Purpose To evaluate tumor shrinking kinetics in order to implement image-guided brachytherapy (IGBT) for the treatment of…
Expand
2016
2016
Adverse impact of bulky (≥ 2 cm) pelvic lymph node involvement determined by magnetic resonance imaging in FIGO stage IIB cervical cancer patients treated with primary concurrent chemoradiation…
T. Kong
,
S. Chang
,
+5 authors
H. Ryu
2016
Corpus ID: 78105660
2016
2016
Laparoscopic radical hysterectomy with lymphadenectomy : our experience
Reprodukcija človeka
,
Reprodukcija človeka
,
izvirni znanstveni članek
,
naše izkušnje
,
L. Meglič
2016
Corpus ID: 56287389
Background: The second most common cancer in women up to 65 years of age is cervical cancer (CC). The same type of cancer is the…
Expand
2006
2006
Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA.
Y. Kornovski
,
G. Gorchev
Journal of B.U.ON. : official journal of the…
2006
Corpus ID: 32698486
PURPOSE To compare the 2-year recurrence-free survival, recurrence rates and their localization after treatment with definitive…
Expand
2002
2002
Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy.
G. Berclaz
,
E. Gerber
,
+4 authors
K. Buser
International Journal of Oncology
2002
Corpus ID: 24816992
Recently randomized trials show an overall survival advantage of 30% for cisplatin-based chemotherapy given concurrently with…
Expand
Review
2000
Review
2000
Primary ovarian rhabdomyosarcoma associated with clear cell carcinoma of the ovary: a case report and review of the literature.
S. Sant'ambrogio
,
A. Malpica
,
B. Schroeder
,
E. Silva
International Journal of Gynecological Pathology
2000
Corpus ID: 28360756
The clinicopathologic and immunohistochemical findings of a case of coexistent primary ovarian rhabdomyosarcoma and clear cell…
Expand
1999
1999
Spontaneous apoptosis as a predictor of radiotherapy in patients with stage IIB squamous cell carcinoma of the uterine cervix.
E. Chung
,
J. Seong
,
+4 authors
Gwi Eon Kim
Acta oncologica
1999
Corpus ID: 31883615
The purpose of this study was to investigate the correlation between the spontaneous apoptotic index (SAI) determined from…
Expand
Review
1998
Review
1998
High dose rate brachytherapy for carcinoma of the cervix: risk factors for late rectal complications.
T. Uno
,
J. Itami
,
+5 authors
Hisao Ito
International Journal of Radiation Oncology…
1998
Corpus ID: 6177723
Highly Cited
1991
Highly Cited
1991
The effect of volume of disease in patients with carcinoma of the uterine cervix.
J. Kovalic
,
C. Perez
,
P. Grigsby
,
M. Lockett
International Journal of Radiation Oncology…
1991
Corpus ID: 26027657
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE